Sobi's UK & Ireland general manager on the business and the commitment to the hemophilia community

12 April 2017

When Swedish Orphan Biovitrum (STO: SOBI) announced its 2016 financial results in February, all eyes were on the Stockholm-based firm’s hemophilia portfolio.

The successful franchise is the result of a collaboration with Bioverativ (Nasdaq: BIVV), the newly-formed hemophilia business spun out from US-based Biogen (Nasdaq: BIIB).

Driving the company’s 61% increase in revenues and 77% increase in sales was the launch of new hemophilia products, Elocta (efmoroctocog alfa, marketed as Eloctate in the USA and other Bioverativ territories) and Alprolix (coagulation Factor IX [recombinant], Fc fusion protein).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK